Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder

References

• McDougle CJ, Goodman WK, Leckman JF et al. Haloperidol addition in fluvoxamine-refractory obsessive–compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry51(4), 302–308 (1994).
   PubMed Web of Science ®Google Scholar
• Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive–compulsive disorder. I. A controlled clinical trial. Arch. Gen. Psychiatry37(11), 1281–1285 (1980).
   PubMed Web of Science ®Google Scholar
• Flament MF, Rapoport JL, Berg CJ et al. Clomipramine treatment of childhood obsessive–compulsive disorder. A double-blind controlled study. Arch. Gen. Psychiatry42(10), 977–983 (1985).
   PubMed Web of Science ®Google Scholar
• DeVeaugh-Geiss J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive–compulsive disorder. Psychopharmacol. Bull.25(1), 36–40 (1989).
   PubMedGoogle Scholar
• Goodwin G FW, Arango C, Baumann P. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur. Neuropsychopharmacol.19(7), 520–532 (2009).
   PubMed Web of Science ®Google Scholar
• Jenike MA. Clinical practice. Obsessive–compulsive disorder. N. Engl. J. Med.350(3), 259–265 (2004).
   PubMed Web of Science ®Google Scholar
• Baumgarten HG, Grozdanovic Z. Role of serotonin in obsessive–compulsive disorder. Br. J. Psychiatry Suppl.35, 13–20 (1998).
   Google Scholar
• Pian KL, Westenberg HG, van Megen HJ, den Boer JA. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (Berl.)140(3), 365–370 (1998).
   PubMed Web of Science ®Google Scholar
• Khanna S, John JP, Reddy LP. Neuroendocrine and behavioral responses to mCPP in obsessive–compulsive disorder. Psychoneuroendocrinology26(2), 209–223 (2001).
   PubMed Web of Science ®Google Scholar
• Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder. Eur. Neuropsychopharmacol.18(5), 364–372 (2008).
   PubMed Web of Science ®Google Scholar
• Millet B, Jaafari N. Treatment of obsessive–compulsive disorder. Rev. Prat.57(1), 53–57 (2007).
   PubMedGoogle Scholar
• Pauls DL, Leckman JF, Towbin KE, Zahner GE, Cohen DJ. A possible genetic relationship exists between Tourette’s syndrome and obsessive–compulsive disorder. Psychopharmacol. Bull.22(3), 730–733 (1986).
   PubMedGoogle Scholar
• Pauls DL, Towbin KE, Leckman JF, Zahner GE, Cohen DJ. Gilles de la Tourette’s syndrome and obsessive–compulsive disorder. Evidence supporting a genetic relationship. Arch. Gen. Psychiatry43(12), 1180–1182 (1986).
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive–compulsive disorder: an open-label study. J. Clin. Psychiatry63(8), 700–703 (2002).
   PubMed Web of Science ®Google Scholar
• Anden NE, Carlsson A, Kerstell J et al. Oral L-dopa treatment of parkinsonism. Acta Med. Scand.187(4), 247–255 (1970).
   PubMedGoogle Scholar
• Baxter LR Jr, Schwartz JM, Mazziotta JC et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive–compulsive disorder. Am. J. Psychiatry145(12), 1560–1563 (1988).
   PubMed Web of Science ®Google Scholar
• Luxenberg JS, Swedo SE, Flament MF et al. Neuroanatomical abnormalities in obsessive–compulsive disorder detected with quantitative X-ray computed tomography. Am. J. Psychiatry145(9), 1089–1093 (1988).
   PubMed Web of Science ®Google Scholar
• Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive–compulsive disorder. Br. J. Psychiatry Suppl. (35), 26–37 (1998).
   PubMedGoogle Scholar
• Hemmings SM, Kinnear CJ, Lochner C et al. Early- versus late-onset obsessive–compulsive disorder: investigating genetic and clinical correlates. Psychiatry Res.128(2), 175–182 (2004).
   PubMed Web of Science ®Google Scholar
• Menzies L, Chamberlain SR, Laird AR et al. Integrating evidence from neuroimaging and neuropsychological studies of obsessive–compulsive disorder: the orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev.32(3), 525–549 (2008).
   PubMed Web of Science ®Google Scholar
• Kim CH, Cheon KA, Koo MS et al. Dopamine transporter density in the basal ganglia in obsessive–compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology55(3–4), 156–162 (2007).
   PubMed Web of Science ®Google Scholar
• van der Wee NJ, Stevens H, Hardeman JA et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive–compulsive disorder shown by [123I]{β}-CIT SPECT. Am. J. Psychiatry161(12), 2201–2206 (2004).
   PubMed Web of Science ®Google Scholar
• Modell JG, Mountz JM, Curtis GC, Greden JF. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive–compulsive disorder. J. Neuropsychiatry Clin. Neurosci.1(1), 27–36 (1989).
   PubMedGoogle Scholar
• Harsanyi A, Csigo K, Demeter G, Nemeth A. [New approach to obsessive–compulsive disorder: dopaminergic theories]. Psychiatr. Hung.22(4), 248–258 (2007).
   PubMedGoogle Scholar
• Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive–compulsive disorder: serotonin and beyond. CNS Spectr.12(2 Suppl. 3), 14–27 (2007).
   Web of Science ®Google Scholar
• Barr LC, Goodman WK, Price LH. The serotonin hypothesis of obsessive compulsive disorder. Int. Clin. Psychopharmacol.8(Suppl. 2), 79–82 (1993).
   PubMed Web of Science ®Google Scholar
• Pigott TA, Pato MT, L’Heureux F et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive–compulsive disorder. J. Clin. Psychopharmacol.11(4), 242–248 (1991).
   PubMed Web of Science ®Google Scholar
• Pigott TA, L’Heureux F, Hill JL et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive–compulsive disorder. J. Clin. Psychopharmacol.12(1), 11–18 (1992).
   PubMed Web of Science ®Google Scholar
• Korsgaard S, Gerlach J, Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur. J. Pharmacol.118(3), 245–252 (1985).
   PubMed Web of Science ®Google Scholar
• Riddle MA, Leckman JF, Anderson GM et al. Tourette’s syndrome: clinical and neurochemical correlates. J. Am. Acad. Child. Adolesc. Psychiatry27(4), 409–412 (1988).
   PubMed Web of Science ®Google Scholar
• Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive–compulsive disorder. Int. Clin. Psychopharmacol.17(1), 37–40 (2002).
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive–compulsive disorder. Mol. Psychiatry11(7), 622–632 (2006).
   PubMed Web of Science ®Google Scholar
• Trethowan WH, Scott PA. Chlorpromazine in obsessive–compulsive and allied disorders. Lancet268(6868), 781–785 (1955).
   PubMedGoogle Scholar
• Altschuler M. Massive doses of trifluoperazine in the treatment of compulsive rituals. Am. J. Psychiatry119, 367–368 (1962).
   PubMed Web of Science ®Google Scholar
• Hussain MZ, Ahad A. Treatment of obsessive–compulsive neurosis. Can. Med. Assoc. J.103(6), 648 passim (1970).
   PubMedGoogle Scholar
• O’Regan JB. Treatment of obsessive–compulsive neurosis. Can. Med. Assoc. J.103(6), 650–651 (1970).
   Google Scholar
• Rivers-Bulkeley N, Hollender MH. Successful treatment of obsessive–compulsive disorder with loxapine. Am. J. Psychiatry139(10), 1345–1346 (1982).
   PubMed Web of Science ®Google Scholar
• Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog. Neuropsychopharmacol. Biol. Psychiatry27(3), 333–346 (2003).
   PubMed Web of Science ®Google Scholar
• Sareen J, Kirshner A, Lander M et al. Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder symptoms? A systematic review. J. Affect. Disord.82(2), 167–174 (2004).
   PubMed Web of Science ®Google Scholar
• Alevizos B, Lykouras L, Zervas IM, Christodoulou GN. Risperidone-induced obsessive–compulsive symptoms: a series of six cases. J. Clin. Psychopharmacol.22(5), 461–467 (2002).
   PubMed Web of Science ®Google Scholar
• Alevizos B, Papageorgiou C, Christodoulou GN. Obsessive–compulsive symptoms with olanzapine. Int. J. Neuropsychopharmacol.7(3), 375–377 (2004).
   PubMed Web of Science ®Google Scholar
• Tranulis C, Potvin S, Gourgue M et al. The paradox of quetiapine in obsessive–compulsive disorder. CNS Spectr.10(5), 356–361 (2005).
   PubMed Web of Science ®Google Scholar
• Association AP. Practice guideline for the treatment of patients with obsessive–compulsive disorder. Am. J. Psychiatry164(Suppl.), 1–56 (2007).
   PubMedGoogle Scholar
• Eapen V RM. Comorbid obsessive compulsive disorder and Tourette syndrome: therapeutic interventions. CNS Drugs13, 173–183 (2000).
   Web of Science ®Google Scholar
• Thomsen PH. Obsessions: the impact and treatment of obsessive–compulsive disorder in children and adolescents. J. Psychopharmacol.14(2 Suppl. 1), S31–S37 (2000).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J. Psychopharmacol.20(1), 97–103 (2006).
   PubMed Web of Science ®Google Scholar
• Shapira NA, Ward HE, Mandoki M et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive–compulsive disorder. Biol. Psychiatry55(5), 553–555 (2004).
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive–compulsive disorder. J. Clin. Psychiatry65(1), 37–43 (2004).
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Nagata T, Hayashida K et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive–compulsive disorder. J. Clin. Psychiatry70(6), 863–868 (2009).
   PubMed Web of Science ®Google Scholar
• Diniz J, Shavitt R, Pereira C et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive–compulsive disorder: a randomized, open-label trial. J. Psychopharmacol. (2009).
   PubMedGoogle Scholar
• Ravindran AV, da Silva TL, Ravindran LN, Richter MA, Rector NA. Obsessive–compulsive spectrum disorders: a review of the evidence-based treatments. Can. J. Psychiatry54(5), 331–343 (2009).
   PubMed Web of Science ®Google Scholar
• Treatment of obsessive–compulsive disorder. The Expert Consensus Panel for obsessive–compulsive disorder. J. Clin. Psychiatry58(Suppl. 4), 2–72 (1997).
   PubMedGoogle Scholar
• NICE. NIfCE. Obsessive Compulsive Disorder: Core Interventions in the Treatment of Obsessive–Compulsive Disorder and Body Dysmorphic Disorder. NICE, London, UK (2005).
   Google Scholar
• Scahill L, Erenberg G, Berlin CM Jr. et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. Neuro Rx3(2), 192–206 (2006).
   Google Scholar
• Kim W, Kim SJ, Yang JC et al. Korean treatments algorithm for obsessive–compulsive disorder 2007. Korean J. Psychopharmacol.18, 338–346 (2007).
   Google Scholar
• Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive–compulsive disorder. Am. J. Psychiatry164(7 Suppl.), 5–53 (2007).
   PubMed Web of Science ®Google Scholar
• Sullivan RM, Talangbayan H, Einat H, Szechtman H. Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience83(3), 781–789 (1998).
   PubMed Web of Science ®Google Scholar
• Zor R, Keren H, Hermesh H, Szechtman H, Mort J, Eilam D. Obsessive–compulsive disorder: a disorder of pessimal (non-functional) motor behavior. Acta Psychiatr. Scand.120(4), 288–298 (2009).
   PubMed Web of Science ®Google Scholar
• Korff S, Stein DJ, Harvey BH. Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry32(2), 348–355 (2008).
   PubMed Web of Science ®Google Scholar
• Campbell KM, de Lecea L, Severynse DM et al. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J. Neurosci.19(12), 5044–5053 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell KM, McGrath MJ, Burton FH. Behavioral effects of cocaine on a transgenic mouse model of cortical–limbic compulsion. Brain Res.833(2), 216–224 (1999).
   PubMed Web of Science ®Google Scholar
• Tsaltas E, Kontis D, Chrysikakou S et al. Reinforced spatial alternation as an animal model of obsessive–compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology. Biol. Psychiatry57(10), 1176–1185 (2005).
   PubMed Web of Science ®Google Scholar
• Choi JS, Kang DH, Kim JJ et al. Left anterior subregion of orbitofrontal cortex volume reduction and impaired organizational strategies in obsessive–compulsive disorder. J. Psychiatr. Res.38(2), 193–199 (2004).
   PubMed Web of Science ®Google Scholar
• Kang DH, Kim JJ, Choi JS et al. Volumetric investigation of the frontal-subcortical circuitry in patients with obsessive–compulsive disorder. J. Neuropsychiatry Clin. Neurosci.16(3), 342–349 (2004).
   PubMed Web of Science ®Google Scholar
• Szeszko PR, MacMillan S, McMeniman M et al. Brain structural abnormalities in psychotropic drug-naive pediatric patients with obsessive–compulsive disorder. Am. J. Psychiatry161(6), 1049–1056 (2004).
   PubMed Web of Science ®Google Scholar
• Kwon JS, Shin YW, Kim CW et al. Similarity and disparity of obsessive–compulsive disorder and schizophrenia in MR volumetric abnormalities of the hippocampus-amygdala complex. J. Neurol. Neurosurg. Psychiatry74(7), 962–964 (2003).
   PubMed Web of Science ®Google Scholar
• Scarone S, Colombo C, Livian S et al. Increased right caudate nucleus size in obsessive–compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res.45(2), 115–121 (1992).
   PubMed Web of Science ®Google Scholar
• Robinson D, Wu H, Munne RA et al. Reduced caudate nucleus volume in obsessive–compulsive disorder. Arch. Gen. Psychiatry52(5), 393–398 (1995).
   PubMed Web of Science ®Google Scholar
• Szeszko PR, Robinson D, Alvir JM et al. Orbital frontal and amygdala volume reductions in obsessive–compulsive disorder. Arch. Gen. Psychiatry56(10), 913–919 (1999).
   PubMed Web of Science ®Google Scholar
• Machlin SR, Harris GJ, Pearlson GD et al. Elevated medial-frontal cerebral blood flow in obsessive–compulsive patients: a SPECT study. Am. J. Psychiatry148(9), 1240–1242 (1991).
   PubMed Web of Science ®Google Scholar
• Rubin RT, Villanueva-Meyer J, Ananth J, Trajmar PG, Mena I. Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive–compulsive disorder and matched normal control subjects. Determination by high-resolution single-photon emission computed tomography. Arch. Gen. Psychiatry49(9), 695–702 (1992).
   PubMed Web of Science ®Google Scholar
• Lucey JV, Costa DC, Blanes T et al. Regional cerebral blood flow in obsessive–compulsive disordered patients at rest. Differential correlates with obsessive–compulsive and anxious-avoidant dimensions. Br. J. Psychiatry167(5), 629–634 (1995).
   PubMed Web of Science ®Google Scholar
• Swedo SE, Pietrini P, Leonard HL et al. Cerebral glucose metabolism in childhood-onset obsessive–compulsive disorder. Revisualization during pharmacotherapy. Arch. Gen. Psychiatry49(9), 690–694 (1992).
   PubMed Web of Science ®Google Scholar
• Benkelfat C, Nordahl TE, Semple WE et al. Local cerebral glucose metabolic rates in obsessive–compulsive disorder. Patients treated with clomipramine. Arch. Gen. Psychiatry47(9), 840–848 (1990).
   PubMed Web of Science ®Google Scholar
• Hansen ES, Hasselbalch S, Law I, Bolwig TG. The caudate nucleus in obsessive–compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int. J. Neuropsychopharmacol.5(1), 1–10 (2002).
   PubMed Web of Science ®Google Scholar
• Perani D, Garibotto V, Gorini A et al.In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive–compulsive disorder. Neuroimage42(1), 306–314 (2008).
   PubMed Web of Science ®Google Scholar
• Pogarell O, Poepperl G, Mulert C et al. SERT and DAT availabilities under citalopram treatment in obsessive–compulsive disorder (OCD). Eur. Neuropsychopharmacol.15(5), 521–524 (2005).
   PubMed Web of Science ®Google Scholar
• Stengler-Wenzke K, Muller U, Barthel H et al. Serotonin transporter imaging with [123I]β-CIT SPECT before and after one year of citalopram treatment of obsessive–compulsive disorder. Neuropsychobiology53(1), 40–45 (2006).
   PubMed Web of Science ®Google Scholar
• Hesse S, Muller U, Lincke T et al. Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder. Psychiatry Res.140(1), 63–72 (2005).
   PubMed Web of Science ®Google Scholar
• Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive–compulsive disorder and serotonin: is there a connection? Biol. Psychiatry20(11), 1174–1188 (1985).
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Kruesi MJ et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive–compulsive disorder. Arch. Gen. Psychiatry49(1), 29–36 (1992).
   PubMed Web of Science ®Google Scholar
• Hollander E, Stein DJ, Saoud JB et al. Effects of fenfluramine on plasma HVA in OCD. Psychiatry Res.42(2), 185–188 (1992).
   PubMed Web of Science ®Google Scholar
• Zahn TP, Kruesi MJ, Swedo SE, Leonard HL, Rapoport JL. Autonomic activity in relation to cerebrospinal fluid neurochemistry in obsessive and disruptive children and adolescents. Psychophysiology33(6), 731–739 (1996).
   PubMed Web of Science ®Google Scholar
• Marazziti D, Rossi A, Gemignani A et al. Decreased platelet 3H-paroxetine binding in obsessive–compulsive patients. Neuropsychobiology34(4), 184–187 (1996).
   PubMed Web of Science ®Google Scholar
• Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB. Peripheral markers of serotonin and dopamine function in obsessive–compulsive disorder. Psychiatry Res.42(1), 41–51 (1992).
   PubMed Web of Science ®Google Scholar
• Lesch KP, Hoh A, Schulte HM, Osterheider M, Muller T. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive–compulsive disorder. Psychopharmacology (Berl.)105(3), 415–420 (1991).
   PubMed Web of Science ®Google Scholar
• Boshuisen ML, den Boer JA. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology (Berl.)152(1), 74–79 (2000).
   PubMed Web of Science ®Google Scholar
• Little KY, Zhang L, Desmond T et al. Striatal dopaminergic abnormalities in human cocaine users. Am. J. Psychiatry156(2), 238–245 (1999).
   PubMed Web of Science ®Google Scholar
• Rosse RB, McCarthy MF, Alim TN, Deutsch SI. Saccadic distractibility in cocaine dependent patients: a preliminary laboratory exploration of the cocaine-OCD hypothesis. Drug Alcohol Depend.35(1), 25–30 (1994).
   PubMed Web of Science ®Google Scholar
• Koizumi HM. Obsessive–compulsive symptoms following stimulants. Biol. Psychiatry20(12), 1332–1333 (1985).
   PubMed Web of Science ®Google Scholar
• Satel SL, McDougle CJ. Obsessions and compulsions associated with cocaine abuse. Am. J. Psychiatry148(7), 947 (1991).
   PubMed Web of Science ®Google Scholar
• Rosse RB, Fay-McCarthy M, Collins JP Jr. et al. Transient compulsive foraging behavior associated with crack cocaine use. Am. J. Psychiatry150(1), 155–156 (1993).
   PubMed Web of Science ®Google Scholar
• Rosse RB, Fay-McCarthy M, Collins JP Jr, Alim TN, Deutsch SI. The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. Addiction89(9), 1097–1104 (1994).
   PubMed Web of Science ®Google Scholar
• Frye PE, Arnold LE. Persistent amphetamine-induced compulsive rituals: response to pyridoxine(B6). Biol. Psychiatry16(6), 583–587 (1981).
   PubMed Web of Science ®Google Scholar
• Kouris S. Methylphenidate-induced obsessive–compulsiveness. J. Am. Acad. Child. Adolesc. Psychiatry37(2), 135 (1998).
   PubMed Web of Science ®Google Scholar
• Kotsopoulos S, Spivak M. Obsessive–compulsive symptoms secondary to methylphenidate treatment. Can. J. Psychiatry46(1), 89 (2001).
   PubMed Web of Science ®Google Scholar
• Pitchot W, Hansenne M, Moreno AG, Ansseau M. Growth hormone response to apomorphine in obsessive–compulsive disorder. J. Psychiatry Neurosci.21(5), 343–345 (1996).
   PubMed Web of Science ®Google Scholar
• Brambilla F, Perna G, Bussi R, Bellodi L. Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation. Psychoneuroendocrinology25(3), 301–310 (2000).
   PubMed Web of Science ®Google Scholar
• Longhurst JG, Carpenter LL, Epperson CN, Price LH, McDougle CJ. Effects of catecholamine depletion with AMPT (α-methyl-para-tyrosine) in obsessive–compulsive disorder. Biol. Psychiatry46(4), 573–576 (1999).
   PubMed Web of Science ®Google Scholar
• Ceccherini-Nelli A, Guazzelli M. Treatment of refractory OCD with the dopamine agonist bromocriptine. J. Clin. Psychiatry55(9), 415–416 (1994).
   PubMed Web of Science ®Google Scholar
• Catalano M, Sciuto G, Di Bella D et al. Lack of association between obsessive–compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am. J. Med. Genet.54(3), 253–255 (1994).
   PubMed Web of Science ®Google Scholar
• Nicolini H, Cruz C, Camarena B et al. DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive–compulsive disorder. Mol. Psychiatry1(6), 461–465 (1996).
   PubMed Web of Science ®Google Scholar
• Frisch A, Michaelovsky E, Rockah R et al. Association between obsessive–compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur. Neuropsychopharmacol.10(3), 205–209 (2000).
   PubMed Web of Science ®Google Scholar
• Cruz C, Camarena B, King N et al. Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive–compulsive disorder with tics. Neurosci. Lett.231(1), 1–4 (1997).
   PubMed Web of Science ®Google Scholar
• Millet B, Chabane N, Delorme R et al. Association between the dopamine receptor D4 (DRD4) gene and obsessive–compulsive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet.116B(1), 55–59 (2003).
   PubMed Web of Science ®Google Scholar
• Di Bella D, Catalano M, Cichon S, Nothen MM. Association study of a null mutation in the dopamine D4 receptor gene in Italian patients with obsessive–compulsive disorder, bipolar mood disorder and schizophrenia. Psychiatr. Genet.6(3), 119–121 (1996).
   PubMed Web of Science ®Google Scholar
• Billett EA, Richter MA, Sam F et al. Investigation of dopamine system genes in obsessive–compulsive disorder. Psychiatr. Genet.8(3), 163–169 (1998).
   PubMed Web of Science ®Google Scholar
• Karayiorgou M, Altemus M, Galke BL et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive–compulsive disorder. Proc. Natl Acad. Sci. USA94(9), 4572–4575 (1997).
   PubMed Web of Science ®Google Scholar
• Karayiorgou M, Sobin C, Blundell ML et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive–compulsive disorder. Biol. Psychiatry45(9), 1178–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Alsobrook JP 2nd, Zohar AH, Leboyer M et al. Association between the COMT locus and obsessive–compulsive disorder in females but not males. Am. J. Med. Genet.114(1), 116–120 (2002).
   PubMed Web of Science ®Google Scholar
• Ohara K, Nagai M, Suzuki Y, Ochiai M. Association between anxiety disorders and a functional polymorphism in the serotonin transporter gene. Psychiatry Res.81(2), 277–279 (1998).
   PubMed Web of Science ®Google Scholar
• Erdal ME, Tot S, Yazici K et al. Lack of association of catechol-O-methyltransferase gene polymorphism in obsessive–compulsive disorder. Depress. Anxiety18(1), 41–45 (2003).
   PubMed Web of Science ®Google Scholar
• Jelliffe SE. Psychopathology of forced movements in oculogyric crises. Nerv. Ment. Dis.151, 550–552 (1932).
   Google Scholar
• Sacks OW, Kohl M. L-dopa and oculogyric crises. Lancet2(7665), 215–216 (1970).
   PubMed Web of Science ®Google Scholar
• Grad LR, Pelcovitz D, Olson M, Matthews M, Grad GJ. Obsessive–compulsive symptomatology in children with Tourette’s syndrome. J. Am. Acad. Child. Adolesc. Psychiatry26(1), 69–73 (1987).
   PubMed Web of Science ®Google Scholar
• Storch EA, Stigge-Kaufman D, Marien WE et al. Obsessive–compulsive disorder in youth with and without a chronic tic disorder. Depress. Anxiety25(9), 761–767 (2008).
   PubMed Web of Science ®Google Scholar
• Sukhodolsky DG, Scahill L, Zhang H et al. Disruptive behavior in children with Tourette’s syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J. Am. Acad. Child. Adolesc. Psychiatry42(1), 98–105 (2003).
   PubMed Web of Science ®Google Scholar
• Como PG, LaMarsh J, O’Brien KA. Obsessive–compulsive disorder in Tourette’s syndrome. Adv. Neurol.96, 249–261 (2005).
   PubMedGoogle Scholar
• Diniz JB, Rosario-Campos MC, Hounie AG et al. Chronic tics and Tourette syndrome in patients with obsessive–compulsive disorder. J. Psychiatr. Res.40(6), 487–493 (2006).
   PubMed Web of Science ®Google Scholar
• Morer A, Lazaro L, Sabater L et al. Antineuronal antibodies in a group of children with obsessive–compulsive disorder and Tourette syndrome. J. Psychiatr. Res.42(1), 64–68 (2008).
   PubMed Web of Science ®Google Scholar
• Perrin EM, Murphy ML, Casey JR et al. Does group A β-hemolytic streptococcal infection increase risk for behavioral and neuropsychiatric symptoms in children? Arch. Pediatr. Adolesc. Med.158(9), 848–856 (2004).
   PubMedGoogle Scholar
• Giedd JN, Rapoport JL, Leonard HL, Richter D, Swedo SE. Case study: acute basal ganglia enlargement and obsessive–compulsive symptoms in an adolescent boy. J. Am. Acad. Child. Adolesc. Psychiatry35(7), 913–915 (1996).
   PubMed Web of Science ®Google Scholar
• Asbahr FR, Negrao AB, Gentil V et al. Obsessive–compulsive and related symptoms in children and adolescents with rheumatic fever with and without chorea: a prospective 6-month study. Am. J. Psychiatry155(8), 1122–1124 (1998).
   PubMed Web of Science ®Google Scholar
• Giedd JN, Rapoport JL, Garvey MA, Perlmutter S, Swedo SE. MRI assessment of children with obsessive–compulsive disorder or tics associated with streptococcal infection. Am. J. Psychiatry157(2), 281–283 (2000).
   PubMed Web of Science ®Google Scholar
• Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive–compulsive disorder. J. Clin. Psychiatry57(7), 303–306 (1996).
   PubMed Web of Science ®Google Scholar
• Pfanner C, Marazziti D, Dell’Osso L et al. Risperidone augmentation in refractory obsessive–compulsive disorder: an open-label study. Int. Clin. Psychopharmacol.15(5), 297–301 (2000).
   PubMed Web of Science ®Google Scholar
• Hollander E, Bienstock CA, Koran LM et al. Refractory obsessive–compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry63(Suppl. 6), 20–29 (2002).
   PubMed Web of Science ®Google Scholar
• Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol.6(4), 397–401 (2003).
   PubMed Web of Science ®Google Scholar
• Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive–compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J. Clin. Psychiatry60(8), 524–527 (1999).
   PubMed Web of Science ®Google Scholar
• Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive–compulsive disorder. J. Clin. Psychiatry61(7), 514–517 (2000).
   PubMed Web of Science ®Google Scholar
• Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive–compulsive disorder: an open study. Can. J. Psychiatry46(4), 356–358 (2001).
   PubMed Web of Science ®Google Scholar
• Crocq MA, Leclercq P, Guillon MS, Bailey PE. Open-label olanzapine in obsessive–compulsive disorder refractory to antidepressant treatment. Eur. Psychiatry17(5), 296–297 (2002).
   PubMed Web of Science ®Google Scholar
• D’Amico G, Cedro C, Muscatello MR et al. Olanzapine augmentation of paroxetine-refractory obsessive–compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry27(4), 619–623 (2003).
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive–compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry65(4), 565–568 (2004).
   PubMed Web of Science ®Google Scholar
• Husted DS, Shapira NA. A review of the treatment for refractory obsessive–compulsive disorder: from medicine to deep brain stimulation. CNS Spectr.9(11), 833–847 (2004).
   PubMed Web of Science ®Google Scholar
• Marazziti D, Pfanner C, Dell’Osso B et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J. Psychopharmacol.19(4), 392–394 (2005).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol.17(3), 115–119 (2002).
   PubMed Web of Science ®Google Scholar
• Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive–compulsive disorder. J. Clin. Psychopharmacol.23(5), 448–450 (2003).
   PubMed Web of Science ®Google Scholar
• Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive–compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry65(8), 1040–1048 (2004).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive–compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol.20(4), 223–226 (2005).
   PubMed Web of Science ®Google Scholar
• Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A. Quetiapine augmentation in obsessive–compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J. Clin. Psychiatry66(1), 73–79 (2005).
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Mundo E, Altamura AC. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a six-month follow-up case series. CNS Spectr.11(11), 879–883 (2006).
   PubMed Web of Science ®Google Scholar
• Moresco RM, Pietra L, Henin M et al. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology32(1), 197–205 (2007).
   PubMed Web of Science ®Google Scholar
• Olver JS, O’Keefe G, Jones GR et al. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder. J. Affect. Disord.114(1–3), 321–326 (2009).
   PubMed Web of Science ®Google Scholar
• Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H. Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive–compulsive disorder in males. Eur. Neuropsychopharmacol.16(6), 446–450 (2006).
   PubMed Web of Science ®Google Scholar
• Miguita K, Cordeiro Q, Siqueira-Roberto J et al. Association analysis between a VNTR intron 8 polymorphism of the dopamine transporter gene (SLC6A3) and obsessive- compulsive disorder in a Brazilian sample. Arq. Neuropsiquiatr.65(4A), 936–941 (2007).
   PubMed Web of Science ®Google Scholar
• Camarena B, Loyzaga C, Aguilar A, Weissbecker K, Nicolini H. Association study between the dopamine receptor D(4) gene and obsessive–compulsive disorder. Eur. Neuropsychopharmacol.17(6–7), 406–409 (2007).
   PubMed Web of Science ®Google Scholar
• Walitza S, Scherag A, Renner TJ et al. Transmission disequilibrium studies in early onset of obsessive–compulsive disorder for polymorphisms in genes of the dopaminergic system. J. Neural Transm.115(7), 1071–1078 (2008).
   PubMed Web of Science ®Google Scholar